Novo Nordisk | NVO - Себестоимость





Себестоимость Изменить Дата
ANI Pharmaceuticals USD 119.8M 5.3M 2026-06
Aurora Cannabis CAD 8.22M 80.38M 2026-03
Bausch Health Companies USD 997M 18M 2026-06
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Canopy Growth CAD 62.98M 9.91M 2026-03
Corcept Therapeutics USD 4.06M 1.18M 2026-06
Drreddys Laboratories INR 32.13B 8.34B 2026-03
Eli Lilly USD 3.27B 309M 2026-06
GlaxoSmithKline GBP 2.07B 192M 2026-06
Merck USD 3.14B 200M 2026-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Novartis USD 3.71B 251M 2026-06
Novo Nordisk DKK 17.1B 3.5B 2026-06
Novo Nordisk DKK 2.66B 10.94B 2026-06
Pacira USD 58.49M 7.75M 2026-06
Perrigo USD 708.9M 65.2M 2026-06
Phibro Animal Health USD 240.42M 2.58M 2025-12
Prestige Brands USD 135.22M 5.54M 2026-06
Sanofi EUR 3.02B 656M 2026-06
Supernus Pharmaceuticals USD 59M 9.97M 2026-06
Zoetis USD 704M 32M 2026-06